Targeting the transmembrane cytokine co-receptor neuropilin-1 in distal tubules improves renal injury and fibrosis.
Yinzheng LiZheng WangHuzi XuYu HongMengxia ShiBin HuXiuru WangShulin MaMeng WangChujin CaoHan ZhuDanni HuChang XuYanping LinGang XuYing YaoRui ZengPublished in: Nature communications (2024)
Neuropilin-1 (NRP1), a co-receptor for various cytokines, including TGF-β, has been identified as a potential therapeutic target for fibrosis. However, its role and mechanism in renal fibrosis remains elusive. Here, we show that NRP1 is upregulated in distal tubular (DT) cells of patients with transplant renal insufficiency and mice with renal ischemia-reperfusion (I-R) injury. Knockout of Nrp1 reduces multiple endpoints of renal injury and fibrosis. We find that Nrp1 facilitates the binding of TNF-α to its receptor in DT cells after renal injury. This signaling results in a downregulation of lysine crotonylation of the metabolic enzyme Cox4i1, decreases cellular energetics and exacerbation of renal injury. Furthermore, by single-cell RNA-sequencing we find that Nrp1-positive DT cells secrete collagen and communicate with myofibroblasts, exacerbating acute kidney injury (AKI)-induced renal fibrosis by activating Smad3. Dual genetic deletion of Nrp1 and Tgfbr1 in DT cells better improves renal injury and fibrosis than either single knockout. Together, these results reveal that targeting of NRP1 represents a promising strategy for the treatment of AKI and subsequent chronic kidney disease.
Keyphrases
- acute kidney injury
- induced apoptosis
- single cell
- chronic kidney disease
- cell cycle arrest
- signaling pathway
- cell death
- rheumatoid arthritis
- minimally invasive
- gene expression
- liver fibrosis
- dna methylation
- epithelial mesenchymal transition
- genome wide
- transforming growth factor
- intensive care unit
- drug delivery
- risk assessment
- end stage renal disease
- cancer therapy
- high throughput
- climate change
- diabetic rats